Posted by Michael Wonder on 04 Jun 2019
FDA approves Lilly’s migraine drug as first ever cluster headache treatment
4 June 2019 - The drug will be priced the same as for migraine on a per milligram basis, but the cost will vary depending on the length of treatment. Emgality for migraines costs $6,900 a year.
Eli Lilly’s migraine treatment Emgality on Tuesday became the first drug to gain U.S. approval for decreasing the frequency of episodic cluster headache attacks, the Food and Drug Administration said.
Emgality belongs to a new class of drugs called CGRP inhibitors that are used to prevent migraines or reduce their frequency. It competes with Ajovy from Teva Pharmaceutical and Amgen’s Aimovig, all approved within months of each other last year, creating a fierce battle for market share. The approval for a second use could help Lilly differentiate Emgality from its rivals.
